New preprint: Deciphering bedaquiline and clofazimine resistance in tuberculosis Philip Fowler, 22nd March 202122nd March 2021 In this preprint we examine 14,151 clinical isolates drawn from the CRyPTIC dataset. Each isolate had its minimum inhibitory concentration (MIC) to bedaquiline and clofazimine measured and hence we were able to identify the transcription regulator Rv0678, as the current main source of elevated MICs to both these drugs. Lindsay Sonnenkalb, who is studying for her PhD with Stefan Niemann, then evolved Mycobacterium tuberculosis strains under sub-lethal concentrations of both compounds and was able to identify 189 different Rv0678 genetic variants that confer elevated MICs to bedaquiline and clofazimine. Detailed modelling of the protein structure allowed us to posit four main resistance mechanisms: impairment of DNA binding, reduction in protein stability, disruption of protein dimerization, and reduction in affinity for its fatty acid ligand. Share this:Twitter Related antimicrobial resistance clinical microbiology publication
antimicrobial resistance New publication: Validating a bespoke 96-well plate for high-throughput drug susceptibility testing of M. tuberculosis 28th August 201829th September 2018 This paper, published in Antimicrobial Agents and Chemotherapy, determines the reproducibility and accuracy of minimum… Share this:Twitter Read More
New preprint: validating antibiotic resistance prediction in our Myco pipeline 9th November 20249th November 2024 Over the last 18 months or so we’ve been designing, coding and testing a Mycobacterial… Share this:Twitter Read More
antimicrobial resistance New software: gemucator 4th September 20184th September 2018 Short for “Genbank Mutation Locator”. A simple Python3 package that if you pass it a… Share this:Twitter Read More